Indictment Casts Doubt On Results In AID Malaria Project

WASHINGTON—The focus of the troubled 15-year U.S. Agency for International Development program to develop a malaria vaccine (The Scientist, July 10, 1989, page 1) has moved from the laboratory to the courtroom as government investigators charge that an attempt to halt a Third World plague may have been used by some scientists as a source of personal gain. One of the leading scientists in the research program has been indicted on felony charges, and at least two other technical invest

Written byJim Anderson
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

WASHINGTON—The focus of the troubled 15-year U.S. Agency for International Development program to develop a malaria vaccine (The Scientist, July 10, 1989, page 1) has moved from the laboratory to the courtroom as government investigators charge that an attempt to halt a Third World plague may have been used by some scientists as a source of personal gain.

One of the leading scientists in the research program has been indicted on felony charges, and at least two other technical investigators plus a former manager of the program are targets of further probes. Moreover, charges of financial mismanagement and incompetence have led some researchers to question the scientific merits of the search for a cheap and universal vaccine against malaria. Two scientists have told The Scientist that they now believe earlier test results are suspect, and that so-called breakthroughs have produced results that could not be duplicated by other labs.

The ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies